NEW YORK (
CHANGE IN RATINGS
was initiated with a neutral rating at Goldman Sachs. $23 price target. Attractive business but facing several challenges.
(JNPR - Get Report)
was upgraded from market perform to outperform at BMO Capital Markets. $25 price target. Valuation call.
was initiated with a buy rating at Brean Murray. $37 price target. Stregnth of orphan drug, Cinryze.
WBC was upgraded to overweight at JPMorgan. Unique buying opportunity.
STOCK COMMENTS / EPS CHANGES
(AA - Get Report)
estimates lowered through 2011, Morgan Stanley said. Should retain defensive appeal despite headwinds. Overweight rating and $13 price target.
numbers raised at Jefferies. Shares of ATU now seen reaching $31, Jefferies said. High-quality first quarter and beat. Buy rating.
Bed Bath & Beyond
estimates increased through 2013, UBS said. Solid results and margin expansion. Maintain $64 price target and neutral rating.
(CVS - Get Report)
target raised at Goldman Sachs. Shares of CVS now seen reaching $44, Goldman Sachs said. Revived credibility yields confidence in growth algorithm. Buy rating.
(EMR - Get Report)
numbers lowered at UBS. Shares of EMR now seen reaching $50, according to UBS. Estimates also lowered on climate weakness and flat year-over-year orders. Neutral rating.
Emerson Electric numbers cut at Citigroup. Shares of EMR now seen reaching $56, according to Citigroup. Estimates also lowered on Thai flood, destocking, and pockets of lower demand. Buy rating.
Emerson Electric target lowered at Goldman Sachs. Shares of EMR now seen reaching $51, Goldman Sachs said. Facing incremental demand weakness. Buy rating.
(KMX - Get Report)
numbers lowered Goldman Sachs. Shares of KMX now seen reaching $29, Goldman Sachs said. Estimates also lowered on softer same-store unit trends. Neutral rating.
CarMax estimates, target cut at Deutsche Bank. Shares of KMX now seen reaching $31, according to Deutsche Bank. Estimates also lowered as company missed volume and profit expectations.
(MU - Get Report)
numbers cut at UBS. Shares of MU now seen reaching $12, according to UBS. Estimates also lowered on DRAM margin erosion. Buy rating.
Micron technology estimates lowered through 2013, Sterne Agee said. Guided NANA-DRAM outlook down. $11 price target and buy rating.
(NFLX - Get Report)
estimates, target lowered at Citigroup. Shares of NFLX now seen reaching $80, according to Citigroup. Estimates also lowered on segment rebuild and disclosure about 2012 losses. Neutral rating.